RANK expression on breast cancer cells promotes skeletal metastasis

Clinical and Experimental Metastasis

Volumn 31, Issue 2, 2014, Pages 233-245

  Blake, Michelle L ^a   Tometsko, Mark ^a   Miller, Robert ^a   Jones, Jon C ^a   Dougall, William C ^a  

^a AMGEN INC   (United States)

Author keywords

Bone metastases; Breast cancer; RANK; RANKL

Indexed keywords

BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; RANK LIGAND;

EID: 84895068517     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9624-3     Document Type: Article

References (36)

1. Solomayer EF et al (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271-278
2. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584-593
3. Lacey DL et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401-419
4. Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18(2):326-335
5. Canon JR et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119-129
6. Canon J et al (2012) RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 135(3):771-780
7. Stopeck AT et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132-5139
8. Smith MR et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810):39-46
9. Fata JE et al (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1):41-50
10. Gonzalez-Suarez E et al (2007) RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 27(4):1442-1454
11. Cao Y et al (2001) IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107(6):763-775
12. Gonzalez-Suarez E (2011) RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 13(4):222-228
13. Beleut M et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7):2989-2994
14. Gonzalez-Suarez E et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103-107
15. Tanos T et al (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(182):182ra55
16. Joshi PA et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299):803-807
17. Asselin-Labat ML et al (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798-802
18. Schramek D et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98-102
19. Jones DH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692-696
20. Armstrong AP et al (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1):92-104
21. Tan W et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548-553
22. Santini D et al (2011) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 6(4):e19234
23. Yoneda T et al (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16(8):1486-1495
24. Kang Y et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537-549
25. Armstrong AP et al (2002) A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277(46):44347-44356
26. Wilson TJ, Singh RK (2008) Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta 1785(2):85-95
27. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588-1594
28. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s-6249s
29. Zheng Y et al (2007) Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40(2):471-478
30. Martin TJ, Gillespie MT (2001) Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone. Trends Endocrinol Metab 12(1):2-4
31. Casimiro S et al (2013) RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS ONE 8(5):e63153
32. Palafox M et al (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72(11):2879-2888
33. Ithimakin S et al (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73(5):1635-1646
34. Korkaya H et al (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47(4):570-584
35. Roodman GD (2002) Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17(11):1921-1925
36. Li J (2012) Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the ISPY1 trial. J Clin Oncol 30 (27 Suppl):2